The Us3 protein kinase encoded by herpes simplex virus type-1 (HSV-1) suppresses apoptosis in infected cells and is sufficient to block apoptosis induced by overexpression of Bad [Proc. Natl. Acad. Sci. 98 (2001) (2003) 6567]. We extend the findings with Bad to demonstrate that Us3 blocks apoptosis induced by overexpression of Bid, a factor parallel to Bad in the apoptotic pathway, and Bax, a factor downstream of Bad in the apoptotic pathway. A previous report suggested that Us3 exerts its effects at a premitochondrial stage [J. Virol. 75 (2001) 5491], but our results suggest that Us3 exerts anti-apoptotic effects downstream of the mitochondria. We show that the kinase activity of Us3 is necessary for Us3 anti-apoptotic effects, because a catalytically inactive form of Us3 was unable to block apoptosis. A second function of Us3, primary envelopment during viral egress, is conserved in the Us3 homologue of Pseudorabies virus (PRV) [J. Gen. Virol. 82 (2001) 2363. Experiments published here demonstrate that PRV Us3 can also block apoptosis induced by Bax, suggesting that the antiapoptotic activity of Us3 is conserved across a-herpesviruses. D
Introduction
Herpes simplex virus type-1 (HSV-1) and herpes simplex virus type-2 (HSV-2) are closely related viruses that are the causative agents of fever blisters (commonly called 'cold sores') and genital herpes infections. HSV infections are a major cause of cornea scarring that can lead to blindness and, in rare cases, lethal encephalitis. Approximately 80% of the United States population has been exposed to HSV, and 25% of the exposed individuals (approximately 20% of the United States population) suffer recurrent reactivation of the viruses. A number of therapeutic agents that target the viral polymerase have proven effective for treating HSV infections; however, drug-resistant strains are now being seen in the clinic (Norfin and Thouvenot, 2003) . To treat these resistant strains, additional therapeutic agents need to be developed, preferably agents that target different viral factors.
The Us3 gene is conserved among all members of the a-herpesvirus family and possesses an easily recognizable kinase domain (McGeoch and Davison, 1986) . The ATPbinding pocket and the catalytic lysine (also called the invariant lysine) can be readily identified (Hanks et al., 1988) and mutation of the invariant lysine to alanine ablates Us3 kinase activity (Ryckman and Roller, in press ). Despite sequence differences in their N-termini, the HSV-1 and Pseudorabies virus (PRV) Us3 proteins possess a conserved function during envelopment of progeny virus at the inner nuclear membrane (Klupp et al., 2001; Reynolds et al., 2001) . While not essential for growth in cell culture (Purves et al., 1987) , an HSV Us3 deletion virus (Us3-) is severely restricted for growth in mice models (Asano et al., 1999 (Asano et al., , 2000 , as is a PRV Us3-in pigs (Kimman et al., 1994) . The decreased virulence of PRV Us3-in pigs was hypothesized to result from defects in virus maturation (Wagenaar et al., 1995) , whereas the decreased growth of HSV Us3-in mice was attributed to apoptosis of infected cells (Asano et al., 1999 (Asano et al., , 2000 . The necessity of HSV-1 Us3 for inhibition of apoptosis in infected cells is well documented (Jerome et al., 1999; Leopardi et al., 1997; ). An anti-apoptotic activity of PRV Us3 has not been reported.
Apoptosis is an active and ordered process by which a cell eliminates itself from a population. Apoptosis is important during embryogenesis, immune cell selection, and in the elimination of damaged or infected cells. Disruption of the apoptotic process is associated with formation of birth defects, development of cancer, and immune deficiencies. Many viruses, including HSV, possess genes that block apoptosis (reviewed in Koyama et al., 2000) . Inhibition of apoptosis is thought to help the virus evade the cell-mediated immune response as well as anti-viral activities induced within the infected cell. For example, baculovirus-encoded IAP proteins inhibit cellular proteases (Bump et al., 1995; Xue and Horvitz, 1995) called caspases that degrade cellular components during apoptosis. Adenovirus (Chiou et al., 1994) and some herpesviruses Marshall et al., 1999; Nava et al., 1997) possess Bcl-2 homologues that block apoptosis at the mitochondria before activation of the caspases. Restoring the ability of an infected cell to progress through apoptosis is an attractive means of treating viral infections. The present study examines the anti-apoptotic activity of HSV-1 and PRV Us3.
A family of pro-survival and pro-apoptotic members called Bcl-2 family members are defined by distinct protein domains that facilitate interactions between other members of the Bcl-2 family. Pro-apoptotic family members, such as Bax, Bid, and Bad, initiate apoptosis by inducing release of cytochrome c and other factors from the mitochondria (reviewed in Antonsson, 2001; Scorrano and Korsmeyer, 2003) . Pro-survival factors, such as Bcl-2, antagonize the activity of pro-apoptotic factors by complexing with and inactivating the pro-apoptotic factors (reviewed in Antonsson, 2001; Scorrano and Korsmeyer, 2003) . Bid and Bad are factors in parallel pathways that induce apoptosis by modulating the activity of Bax or Bak, factors that appear to directly mediate release of cytochrome c from mitochondria. Proteolytic cleavage of Bid or Bad stimulates their ability to activate Bax (or Bak), and the activity of Bad can additionally be regulated by phosphorylation of Bad on Ser-112 by RSK (Bonni et al., 1999; Fang et al., 1999) , Ser-136 by Akt (Datta et al., 1997; Fang et al., 1999) (also called protein kinase B), and Ser-155 by protein kinase A (Lizcano et al., 2000; Tan et al., 2000; Virdee et al., 2000; Zhou et al., 2000) . When phosphorylated on Ser-112 and -136, Bad is inactive because it is sequestered by 14-3-3 proteins (reviewed in Tzivion et al., 2001) . When dephosphorylated, Bad is active and capable of interacting with Bcl-2, and this competition for Bcl-2 effectively releases Bax from Bax:Bcl-2 dimers and allows Bax to homodimerize and disrupt the mitochondria (reviewed in Antonsson, 2001; Scorrano and Korsmeyer, 2003) . Bid appears to directly bind Bax and induce an activating conformational change in Bax that promotes Bax-mediated cell killing (Desagher et al., 1999) .
A previous report ) demonstrated that Us3 is sufficient to block apoptosis induced by overexpression of Bad. Inhibition of apoptosis was correlated with phosphorylation of Bad on Ser-112 and Ser-136-the two critical serines known to be targeted by cellular kinases. More recently, phosphorylation of Bad at these two serines was shown to be not essential for Us3 anti-apoptotic activity (Benetti et al., 2003) . The anti-apoptotic activity of Us3 correlated with inhibition of proteolytic processing of Bad, suggesting that Us3 may act on a caspase upstream of Bad.
We confirm that Us3 can block apoptosis induced by a non-phosphorylatable mutant of Bad and extend the findings to demonstrate that Us3 is sufficient to block apoptosis induced by overexpression of Bid, a factor parallel to Bad in the apoptotic pathway. Furthermore, Us3 was able to block apoptosis induced by overexpression of Bax, which demonstrates that Us3 can exert anti-apoptotic effects downstream of Bad. A kinase inactive mutant of Us3 was used to demonstrate that inhibition is dependent upon Us3 catalytic activity. Lastly, we show that Us3 antiapoptotic activity may be conserved across a-herpesviruses, as PRV Us3 was also demonstrated to block apoptosis induced by Bax.
Results
Overexpression of pro-apoptotic Bcl-2 family members caused a marked reduction in the number of GFP-expressing cells
We adapted an assay for apoptosis that measures GFP expression from an inducer plasmid (Schimmer et al., 2001) . Inducer plasmids contain sequences that direct the expression of both a reporter gene (GFP) and an apoptotic inducer (Bax, Bid, Bad, or a non-phosphorylatable mutant of Bad [Bad-AA]). Apoptosis is measured as the difference in the apparent transfection efficiency of inducer plasmids to a GFP expression plasmid that lacks inducers. Differences in the number of GFP-expressing cells were evident by fluorescence microscopy in HEp-2 cells at 24 h (data not shown), at which point cells were harvested and the percentage of GFP positive cells quantified by flow cytometry. Within a given experimental trial, the data were normalized to cells transfected with GFP alone as the number of GFP positive cells in the inducer condition divided by the number of GFP positive cells in the GFP condition. The ratios obtained in any individual experimental trial were consistent with ratios obtained in other experimental trials ( P < 0.01). As seen in Fig. 1 , markedly fewer GFP positive cells were observed when cells were transfected with inducer plasmids. While transfection with Bax or Bid reduced the number of GFP-expressing cells by 50-60%, transfection with Bad or Bad-AA (the non-phosphorylatable form of Bad) reduced the number by about 30%. A similar pattern in the number of GFP-expressing cells was obtained using three independently prepared sets of plasmid DNAs, suggesting that the differences are not the result of variations in plasmid preparations.
Bcl-2 and Us3 partly restored the apparent transfection efficiency in inducer conditions, whereas Us3-K220A and B-gal did not
To confirm that the differences in the percentage of GFP-expressing cells were the result of apoptosis and not unrelated differences in transfection efficiency, Bcl-2 (a factor that antagonizes the activity of Bax, Bid, or Bad) was cotransfected with the inducer plasmids. As seen in Figs. 2A -D, coexpression of Bcl-2 efficiently increased the number of GFP-expressing cells in the Bax, Bid, Bad, and Bad-AA conditions. If rescue had been complete, the column would have extended up to the dashed line. Cells that were not rescued may have expressed Bcl-2 at insufficient levels to protect or may have picked up the inducer plasmid without picking up the rescue plasmid. Expression of B-gal was included as a negative control, because B-gal has never been reported to possess antiapoptotic activity. Coexpression of B-gal caused no significant increase in the number of GFP-expressing cells in any of the inducer conditions, demonstrating that rescue by Bcl-2 is specific. We then tested the ability of wild-type Us3 and of Us3-K220A, a kinase inactive form of Us3 (Ryckman and Roller, in press) , to increase the number of GFP-expressing cells. Us3 was as efficient at rescuing cells from death as Bcl-2, whereas Us3-K220A was as efficient as the negative control. This demonstrates that Us3 is able to block apoptosis induced by a variety of Bcl-2 family members and that the catalytic activity of Us3 is necessary for this function. Furthermore, because Us3 rescues from Bad-AA-mediated cell death, Us3-induced phosphorylation of Bad at those residues is not necessary for Us3 inhibition of apoptosis.
Indirect immunofluorescence revealed a large number of cells with cleaved PARP in inducer conditions rescued with empty vector, Us3-K220A and B-gal, but not Bcl-2 or Us3
We confirmed the results from our GFP assay with a second apoptosis assay based on positive markers of apoptosis. One late effect during apoptosis is caspasemediated cleavage of PARP, a DNA repair enzyme (Fig. 8, step 6a) . Using an antibody that recognizes only the cleaved form of PARP, we immunostained and examined coverslips of HEp-2 cells transfected with various combinations of inducer and rescue plasmids by microscopy. High-powered magnification revealed brightly labeled cells with a blebby apoptotic morphology on a background of lightly labeled cells with a healthy spindleshaped morphology (Fig. 3A) . At a lower power, few cells stained positive for cleaved PARP when cells were transfected with a GFP expression construct (Fig. 3B ), but large numbers were observed when inducer plasmids were cotransfected with pcDNA ( Figs number observed in the empty vector rescue condition. These results confirm that Us3 is capable of blocking apoptosis induced by several different members of the Bcl-2 family and, specifically, that the kinase activity of Us3 is necessary for this inhibition and that phosphorylation of Bad at serines 112 and 136 is not necessary for Us3 inhibition of apoptosis.
Western blots demonstrate protein expression from the inducer plasmids
Expression of the apoptotic inducers in the various rescue conditions was demonstrated by Western blotting. None of the inducers were detected in lysates of cells transfected with a GFP expression construct, but inducers were observed in lysates of cells transfected with the respective inducer plasmid (Figs. 5A -D) . Each lane was loaded with 50 Ag of protein and equal loading was further demonstrated by Western blots for actin. Expression of apoptotic inducers was roughly equal between the Bcl-2 and Us3 conditions, suggesting that Us3 does not protect from apoptosis by inducing degradation or otherwise altering expression of the pro-apoptotic Bcl-2 family members.
Western blots demonstrate protein expression from the rescue plasmids Expression of Bcl-2, Us3, or Us3-K220A in the various rescue conditions was demonstrated by Western blotting. Rescue proteins were not detected in lysates of cells transfected with GFP alone, but were observed in lysates of cells transfected with the respective rescue plasmid (Figs. 6A -C) . Each lane was loaded with 50 Ag of protein and equal loading was further demonstrated by Western blots for actin. As seen in Fig. 6B , the Us3 polyclonal antibody reacted with one band from cell lysates of uninfected cells. That band is observed in all lysates tested, suggesting that the antibody reacts nonspecifically with a cellular protein. Three bands were evident in lysates from HSV-infected cells: the nonspecific band and two additional bands that correlate in size with the specific doublet that Us3 separates as in SDS-PAGE . A similar pattern was observed in lysates of cells transfected with the Us3 rescue plasmid. As seen in Fig. 6C , Us3-K220A appears to run as a single band in SDS-PAGE, above the nonspecific band. The amount of Us3-K220A and Us3 expressed in transiently transfected cells appears similar, suggesting that Us3-K220A is stable and accumulates to levels comparable to that of Us3. This suggests that the inability of Us3-K220A to rescue cells from apoptosis is not the result of lower expression or stability of Us3-K220A, but is the result the mutation in the kinase domain. PRV Us3 was as efficient as HSV-1 Us3 at rescuing cells from apoptosis
As represented in Fig. 7A , HSV-1 and PRV Us3 protein sequence homology are restricted to the kinase domain. Nterminal sequences appear unrelated, and the PRV N-terminus is much shorter than the HSV-1 N-terminus. While both proteins have been reported to affect viral egress from the nucleus (Klupp et al., 2001; Reynolds et al., 2001) , PRV Us3 has not been reported to possess anti-apoptotic activity. We were interested in determining if the N-terminal portion of HSV-1 Us3 directed anti-apoptotic activity, or if the anti- apoptotic activity of Us3 was conserved among a-herpesviruses. The ability of the PRV Us3 to rescue cells from Baxinduced apoptosis was measured in the GFP assay. FLAGtagged versions of both PRV and HSV-1 Us3 were cloned and coexpressed with the Bax inducer plasmid. The FLAGtag did not appear to hinder HSV-1 Us3 anti-apoptotic activity, as HSV-1 Us3-FLAG was as efficient at rescuing cells from death as Bcl-2. Because PRV Us3 was as efficient as HSV Us3 and Bcl-2 at rescuing cells from death, we conclude (i) that the unique N-terminal sequences of HSV-1 Us3 do not specifically direct HSV-1 Us3 anti-apoptotic activity and (ii) that Us3 anti-apoptotic activity is conserved in PRV.
Discussion
A schematic depicting the relevant steps in the apoptotic pathway is shown in Fig. 8 . Because Us3 inhibition of apoptosis is not dependent upon phosphorylation of Bad (Benetti et al., 2003) (Fig. 8, step 1a) , we considered the possibility that Us3 inhibition of apoptosis was independent of Us3 kinase activity altogether. In such a model, Us3 would function similar to Bcl-2 or an IAP and block apoptosis by binding to and inactivating pro-apoptotic 2 ) were cotransfected with Bax and various combinations of rescue plasmids. Relative numbers of GFP-positive cells were determined as in Fig. 2 . Columns represent the mean and error bars represent the standard deviation of five experiments. Student's t test analysis demonstrated significance ( P < 0.002) of the differences between Bcl-2, HSV-1 Us3 or PRV Us3, and vector or B-gal. Fig. 8 . Schematic of relevant apoptotic events. Three parallel pathways (steps 1a, 1b and 1c) are able to disrupt Bcl-2:Bax dimers to promote Baxinduced release of cytochrome c (step 3) from the mitochondria to the cytoplasm. Once in the cytoplasm, cytochrome c interacts with APAF-1 to form a complex that activates caspase-9 (step 4). Caspase-9, an initiator caspase, cleaves caspase-3 to an active form (step 5). Once active, caspase-3 degrades numerous cellular factors to mediate a multitude of apoptotic effects (step 6a), including translation inhibition (cleavage of eIF4G), shutdown of DNA repair (cleavage of PARP), degradation of genomic DNA (indirectly by cleaving DFF/ICAD), and activation of Bad and/or Bid in a positive feedback loop (step 6b) that further promotes apoptosis. Us3 may block programmed cell death at two points in the apoptotic pathway (shaded boxes).
factors. We tested this hypothesis by measuring the ability of Us3-K220A, a kinase inactive form of Us3, to rescue cells from apoptosis induced by overexpression of Bcl-2 family members. Critical amino acids in the kinase domain of Us3 can easily be identified by sequence alignment with other serine/threonine kinases (reviewed in Hanks et al., 1988) . Mutation of the invariant lysine to alanine is known to ablate the activity of serine/threonine kinases and was also effective at eliminating Us3 catalytic activity (Ryckman and Roller, in press ). Experiments with Us3-K220A demonstrated that the kinase activity of Us3 is required for antiapoptotic function.
We note seemingly disparate results in the ability of Bad and Bad-AA to induce apoptosis between the GFP assay and the PARP assay. The two assays are categorically different in that the GFP assay measures an endpoint of accumulated cells lost and the PARP assay measures the number of cells undergoing apoptosis in a population at a particular moment in time. One explanation for the seemingly disparate results could be that apoptosis induced by Bax or Bid proceeds rapidly, whereas apoptosis proceeds relatively slowly when induced by Bad. In such a case, fewer cells would be captured in the process of apoptosis at any given time in Bax-or Bid-induced conditions than would be captured in Bad-induced conditions.
An extensive body of literature has demonstrated that the HSV Us3 is necessary for inhibition of apoptosis in infected cells. Inhibition of apoptosis was found to occur at a premitochondrial stage (Fig. 8, steps  1 or 2) . A 2001 report demonstrated that Us3 was sufficient to block apoptosis induced by overexpression of Bad ). Inhibition of apoptosis correlated with phosphorylation of Bad on two critical serines, suggesting that Us3 exerted its anti-apoptotic effects by inhibiting Bad activity (Fig. 8, step 1a) . A more recent publication by the same group demonstrated that Us3 blocked apoptosis induced by overexpression of a nonphosphorylatable mutant of Bad (Benetti et al., 2003) . Proteolytic processing of Bad was inhibited by Us3, suggesting that Us3 may act on caspases at a point upstream of Bad in the apoptotic pathway (Fig. 8, step 6b) . In this publication, we confirm that Us3 can block apoptosis induced by overexpression of Bad or a non-phosphorylatable form of Bad (Bad-AA), and further demonstrate that Us3 can block apoptosis induced by overexpression of Bid (a factor parallel to Bad in the apoptotic pathway) and Bax (a factor downstream of Bad in the apoptotic pathway). Our data suggest that Us3 may block caspase activity at a point downstream of mitochondrial events (Fig. 8, steps 3, 4 , 5, or 6). Because caspase-3, a factor downstream of Bax, has been shown to cleave pro-apoptotic Bad in a feedback loop (Condorelli et al., 2001) (Fig. 8, step 6b) , the previously reported anti-apoptotic activities of Us3 upstream of Bad may actually be the result of Us3 activities downstream of Bax. We can rule out an alternate hypothesis that Us3 blocks apoptosis by inducing degradation of Bax, Bid, or Bad because Western blots demonstrated roughly equal expression of inducer genes between the Bcl-2 and Us3 conditions.
While phosphorylation of Bad is not necessary for Us3 inhibition of apoptosis, Us3 induction of Bad phosphorylation may be one of multiple protective effects. The optimal consensus sequence targeted by the Pseudorabies virus (PRV) Us3 homologue has been defined as RRRXS/TZ, where X is any amino acid and Z is not an acidic amino acid (Purves et al., 1986 ). An increase in the number of spacer amino acids between the arginines and the serine did not dramatically affect affinity for the target if the target contained three arginines (Leader et al., 1991) . A 25-fold decrease in affinity for substrate was observed if the substrate possessed only two arginines, and a further threefold decrease was observed if such substrates have an additional spacer amino acid between the arginines and the serine. The HSV-1 Us3 has been demonstrated to behave similar to the PRV homologue (Purves et al., 1986) . We have grouped potential phosphorylation sites in apoptotic regulators according to their similarity to the PRV consensus, where we define an optimal Us3 consensus as RRRXS/ TZ, RRRXXS/TZ, or RRRXXXS/TZ, a moderate consensus as RRXS/TZ or RRXXS/TZ, and sequences without upstream arginines as not substrates. By our definitions, Ser-112 and Ser-136 of Bad fall within moderate Us3 consensus sequences (Table 1) and may be direct targets of Us3. During HSV infection, Us3 may phosphorylate Bad to block apoptosis at a premitochondrial stage (Fig. 8, steps 1 and 2 ) in addition to a factor downstream of Bax (Fig. 8, steps 3, 4 , 5, or 6) as a redundant anti-apoptotic effect. Interestingly, the consensus sequence recognized by Us3 is similar to the consensus recognized by Akt (RXRXXS/TO, where X is any amino acid and O is a bulky hydrophobic amino acid) (Alessi et al., 1996) . Akt has been shown to phosphorylate a large number of factors to promote cell survival, including Bad, caspase-9, forkhead transcription factors, and InB kinase. Us3 could promote cell survival by directly targeting some of these factors or, alternatively, by inducing Akt activity. In addition to Akt targets, several other apoptotic regulators have been demonstrated to have their activity modulated by phosphorylation. We have examined the sequence of Bax, Bid and sixteen other apoptotic regulators previously shown to be phosphorylated (see Table 1 ) for the presence of a Us3 consensus sequence. Neither Bax nor Bid possess a serine or threonine in a Us3 consensus sequence; however, a strong Us3 consensus was observed around Ser-196 of caspase-9. Akt phosphorylation of Ser-196 inactivates caspase-9 (Cardone et al., 1998) , and phosphorylation of caspase-9 (by Us3 directly or by Us3-induced Akt activity) could be a single event responsible for our downstream and the previously reported upstream anti-apoptotic effects of Us3. Caspase-9 is downstream of Bax in the apoptotic pathway, but upstream of caspase-3, which has been shown to cleave Bad (Condorelli et al., 2001) (Fig. 8, step 6b) . Studies examining the importance of caspase-9 Ser-196 phosphorylation are presently underway.
The a-herpesvirus family can be subdivided into the Simplex and Varicello genera based on molecular criteria and sequence analysis (McGeoch and Cook, 1994; Roizman et al., 1992) . Us3 proteins in both genera have been reported to possess a conserved function in primary envelopment (Klupp et al., 2001; Reynolds et al., 2001 ). Anti-apoptotic activity has been ascribed to Us3 in HSV-1 and HSV-2 of the Simplexviruses, but such an activity has not been identified for Us3 in a member of the Varicelloviruses. PRV Us3 was selected as a representative Varicellovirus to determine if the anti-apoptotic activity of Us3 is conserved between a-herpesvirus genera. Because sequence homology between PRV and HSV-1 Us3 is restricted to the kinase domain, we were also able to determine if the nonconserved N-terminal portion of HSV-1 Us3 directed Us3 anti-apoptotic activity. Our results demonstrated that PRV Us3 was as efficient as HSV-1 Us3 at rescuing cells from apoptosis induced by Bax, suggesting that the anti-apoptotic activity of Us3 is conserved among a-herpesvirus family members. Additionally, the N-terminal sequences of HSV-1 Us3 not shared with PRV Us3 are not uniquely required for prevention of Bax-induced apoptosis.
The efficacy of delivering of pro-survival genes, such as Bcl-2, as therapeutic treatment after ischemia (Zhao et al., 2003) or for diseases such as Alzheimer's (Maguir-Zeis et al., 2001) is being tested. Us3 is a promising therapeutic anti-apoptotic factor, because although Bcl-2 is required in stoichiometric amounts, Us3 anti-apoptotic activity is catalytic and, presumably, small amounts of Us3 would need to be expressed or delivered. An additional advantage of Us3 over Bcl-2 is that Us3 kinase activity can be inhibited with xanthate derivatives (Walro and Rosenthal, 1997) , suggesting that Us3 activity could be modulated after gene delivery if anti-Us3 drugs with low toxicity can be identified.
A number of nucleotide analogs that target the viral polymerase have been effectively used to treat HSV in the clinic. HSV strains resistant to existing drug treatments are appearing, and new therapies are needed that will target a different portion of the viral lifecycle (Norfin and Thouvenot, 2003) . Drugs that inhibit Us3 activity could be useful for treating HSV infections, because a Us3 deletion virus was less virulent and propagated less efficiently than a WT virus in mice (Asano et al., 2000; Asano et al., 1999) . Identification of Us3 interacting partners and mapping of the interacting domains may allow for the design of drugs that specifically inhibit Us3.
Materials and methods

Cell culture
HEp-2 cells, originally obtained from ATCC, were maintained in growth media consisting of DMEM (GibcoBRL) + 5% FCS (GibcoBRL) + 100 U/ml Pen and 100 Ag/ml Strep (GibcoBRL). Cells were carried for no more than 15 passages. 
Plasmids
To create the GFP expression construct (pRR1166), EGFP was PCR amplified (left-GGAAGGCGCCACGTTAAC-CATGGTGAGCAAGGGC right-ATATCGGTCCGTT-TA AACCGGT TACTTGTA CAGCTCGTCC) from pIRESpuro-EGFP (ClonTech), digested with SfoI and RsrII, and ligated into the approximately 4700-bp fragment of RsrII and BsaBI digested pcDNAIII (Invitrogen). This removed most of the neomycin resistance gene and placed EGFP under control of the sv40 promoter, although leaving the multicloning site (MCS) available for subsequent use. Bax, HA:Bad, and HA:Bad-AA (Zha et al., 1996) were cloned into the EcoRI site of the pRR1166 MCS by digesting the Korsmeyer pSFFV plasmids with EcoRI to create the inducer plasmids pRR1187, pRR1179, and pRR1197, respectively. A frameshift in the coding sequence of our pSFFV Bid plasmid (Wang et al., 1996) was corrected by PCR amplification (left-GCTGGAATTCTGATGGACTGTG right-TGCAGAATT-CAGTCCATCCCATT). The PCR product was digested with EcoRI and cloned into the EcoRI site of pRR1166 to create the inducer plasmid pRR1184. The Bcl-2 expression construct was created by digesting the Bcl-2 pSFFV plasmid (Hockenbery et al., 1990) with EcoRI and cloning into the EcoRI site of pcDNAIII to create pRR1138. pRR1098, the Us3 expression construct, is described elsewhere (Reynolds et al., 2001) . Plasmid pRR1203 encodes a mutant Us3, in which lysine 220 is mutated to alanine (Us3-K220A) and has been described elsewhere (Ryckman and Roller, in press ). The FLAG-tagged Us3 expression construct, pRR1206, was created by PCR amplification from pRR1098 (left-GATC-G A AT T C G C G A AT G G C C T G T C G TA A G T r i g h t -GCGGTCTAGATCATTTATCATCATCATCCTTA-TAGTCTTTCTGTTGAAACAGCGGCA), digestion with EcoRI and XbaI, and ligation into EcoRI and XbaI digested pcDNAIII. The PRV FLAG-tagged Us3 expression construct, pRR1207, was created by PCR amplification from P RV ( K a ) ( l e f t -G AT C G A AT T C A A C A AT G G C C -GACGCCGGAAT right-GATCTCTAGATTATTTATCAT-CATCATCCTTATAGTCTACGGTCCACATTCCAAAGT), digestion with EcoRI and XbaI, and ligation into EcoRI and XbaI digested pcDNAIII. h-galactosidase (B-gal) was expressed from pCMVh (ClonTech).
Transfections
Transfection efficiencies of 25 -50% were routinely obtained with 1.0 Ag of plasmid (0.2 Ag inducer and 0.8 Ag rescue) and 5 Al LipofectAMINE Reagent (Invitrogen) per well of a 12-well dish (4.5 cm 2 ) of HEp-2 cells. Briefly, 1.0 Al of DNA was added to 34 Al of DMEM, and 5 Al of LipofectAMINE was added to 30 Al of DMEM. These DNA and LipofectAMINE solutions were combined, vortexed briefly, and 300 Al of DMEM added promptly. Within 5 min, the resultant, approximately 375-Al solution, was added to a single well of DMEM-washed HEp-2 cells (70% confluent) and incubated for 60 min at 37 jC. The cells were washed once with supplemented growth media (DMEM + 10% FBS + Pen/Strep) and the cells were incubated in supplemented growth media for 24 h at 37 jC. For transfections in 6 wells, the amounts and volumes of the reagents were doubled. Please note that the incubation times in our optimized transfection procedure differ from those recommended by the manufacturer.
Cell harvesting
For flow cytometry, 24 h after transfection, cells were harvested with trypsin, added back to the growth media and then centrifuged at 6000 rpm (3000 Â g) at room temperature (RT) for 4 min. Cells were washed twice with PBS and finally resuspended in 200-Al PBS. Intensity of the GFP fluorescence of intact cells was recorded using the CellQuest Pro software package (Becton Dickinson, Inc.) on a FACSCaliber (Becton Dickinson, Inc.) and analyzed with the FloJo version 3.4 software package (Tree Star, Inc.).
For Western Blotting, 18 h after transfection, cells were scraped from the dish in the growth media and then centrifuged at 6000 rpm (3000 Â g) at RT for 4 min. Cells were washed once with PBS before 88 Al of WCE Buffer (20 mM HEPES, pH 7.2; 0.5% NP-40; 5 mM EDTA; 5 mM EGTA; and 10 mM NaF) was added and cells were vortexed twice at medium speed for 5 -10 s. Cells were incubated on ice for 5 min, 7 Al of 5 M NaCl was added, and cells were incubated on ice for 30 min. The solution was then centrifuged at 14 000 rpm (16 000 Â g) for 10 min at 4 jC. The supernatant was moved to a fresh tube and protein concentration determined by Bradford Assay (Bio-Rad), according to the manufacturers protocol.
Western blotting
Total protein (50 Ag) was run on each lane of a 15% polyacrylamide gel (with a 6% stacking gel). After SDS-PAGE, efficient transfer to a Protran nitrocellulose membrane (Schleicher and Schuell) was checked with Ponceau S (0.5% Ponceau S, 1% acetic acid) and the blot was then blocked in T-TBS (20 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween-20, 0.05% sodium azide) + 5% nonfat dried milk (NFDM) overnight at RT. Blots were washed twice with T-TBS, exposed to primary antibodies (in T-TBS) for 2+ h at RT, washed twice, exposed to secondary antibodies (in T-TBS) for 1 h at RT, and washed 3 times. Blots were then exposed to ECL reagents (Amersham-Pharmicia Biotech) in the dark for 2 min and images obtained on Hyperfilm ECL (Amersham-Pharmicia Biotech).
Immunofluorescence
For immunofluorescence to detect cleaved PARP, 15 h after transfection, coverslips of HEp-2 cells were fixed in 2% formaldehyde in PBS for 10 min. Cells were washed with PBS for 5 min and incubated for at least 2 h in IF Buffer (0.5% Triton X-100, 0.5% sodium deoxycholate, 1.0% BSA, and 0.05% sodium azide in PBS). Coverslips were then treated with 40 Al of primary stain (rabbit antiCleaved PARP [Promega] diluted 1:400 in IF Buffer), washed once with PBS, and then treated with 40 Al of secondary stain (Texas Red-conjugated goat anti-Rabbit [Molecular Probes] diluted 1:400 in IF Buffer). Coverslips were washed twice with PBS, mounted onto glass slides, and viewed on a BX-51 Light Microscope (Olympus, Inc.) using a 'Spot' CCD Camera and software (Diagnostics Instruments, Inc).
Quantification of PARP-positive cells
Digital images of microscopic fields were taken such that brightly labeled apoptotic cells could clearly be discriminated from light background labeling of healthy cells and lightly labeled healthy cells could clearly be discriminated from dark regions where no cells existed. Using the histogram feature of Adobe PhotoShop (Adobe, Inc), the pixels in each digital image were scored as dark (no cells) or not dark (consisting of both healthy and apoptotic cells) to obtain a relative percent of cell confluence for each digital image. The number of brightly labeled cells in a given digital image was divided by the confluence of the cells in that image to obtain the number of brightly labeled cells per confluent monolayer for that digital image. Ten digital images were examined for each rescue condition in five replicate experiments.
Antibodies
The following primary antibodies were used in Western Blotting at the indicated concentrations; Mouse anti-Bax (Sigma, clone 6A7) was used at 10 Ag/ml, Rabbit anti-Bid (Cell Signaling Technologies) was used at a 1:1000 dilution, Rabbit anti-Bad (Cell Signaling Technologies) was used at a 1:1000 dilution, Rabbit anti-Us3 (a generous gift of Bernard ) was used at 1:1000, Hamster anti-Bcl-2 (Pharmingen, clone 6C8) was used at 1:1000, and Mouse anti-actin (Sigma, clone AP-40) was used at 1:1000. HRP-secondary antibodies were used at 1:1000 dilution in Western blotting; Sheep anti-Mouse (Amersham), Goat antiRabbit (Santa Cruz Biotechnology), and Goat anti-Hamster (Caltag).
